A Swedish pharmaceutical company has been awarded a $1.8 billion contract to sell a number of its environmental protection properties, including a greenhouse facility and its greenhouse processing facilities.
Environmental Protection Agency (EPA) spokeswoman Kirsten Jansson said Astrazenec was awarded the contract on Thursday, but the agency did not say when or how much the deal would be worth.
“We will make it public as soon as possible,” she said.
The environmental protection unit of Astrazenac said it would sell its assets, including the greenhouse facility, which it said would be operated under the EPA’s Greenhouse Gas Reduction Initiative.
Astrazeneca, which is part of the AstraZeneca Group, has been under pressure from environmental groups over the years.
In 2014, it received a $3 billion federal grant that was supposed to help it deal with the effects of climate change.
Last year, the company pleaded guilty to violating federal rules requiring it to buy greenhouse emissions permits.
The agreement with EPA will give the company time to implement its greenhouse emissions reductions program, Astrazenica said.
The Astrazenocan plant is set to be converted into a biomass facility that will capture the carbon dioxide released during the production of the company’s cosmetics and other products.
Jansson said the EPA did not immediately have information about the potential sale.